5-acetyl-1-ethylimidazole | 602306-51-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-acetyl-1-ethylimidazole
• 英文别名: 1-(1-Ethyl-1H-imidazol-5-yl)ethan-1-one；1-(3-ethylimidazol-4-yl)ethanone
• CAS: 602306-51-4
• 化学式: C₇H₁₀N₂O
• mdl: MFCD08668277
• 分子量: 138.169
• InChiKey: XGWKQVJEEPQMLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] DERIVATIVES OF 4- (IMIDAZOL-5-YL)-2-(4-SULFOANILINO) PYRIMIDINE WITH CDK INHIBITORY ACTIVITY<br/>[FR] DERIVES DE 4- (IMIDAZOL-5-YL)-2-(4-SULFOANILINO) PYRIMIDINE A ACTIVITE INHIBITRICE CDK
  申请人：ASTRAZENECA AB

  公开号：WO2003076436A1

  公开（公告）日：2003-09-18

  Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  公式（I）的化合物：其中R1、R2、R3、R4、R5和p的定义如下，并且描述了药学上可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效果的药物。
• Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
  申请人：Newcombe John Nicholas

  公开号：US20050131000A1

  公开（公告）日：2005-06-16

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  本文描述了化学式（I）的化合物，其中R1、R2、R3、R4、R5和p的定义如本文中所述，并描述了其药物学上可接受的盐和体内可水解的酯。同时还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生对温血动物（如人）的细胞周期抑制（抗细胞增殖）效应的药物。
• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150353505A1

  公开（公告）日：2015-12-10

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了公式（I）的化合物或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如此定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗心血管，平滑肌，肿瘤，神经病理，自身免疫，纤维化和/或炎症性疾病的方法。
• DERIVATIVES OF 4-(IMIDAZOL-5-YL)-2-(4-SULFOANILINO)PYRIMIDINE WITH CDK INHIBITORY ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1487823A1

  公开（公告）日：2004-12-22
• US7465728B2
  申请人：——

  公开号：US7465728B2

  公开（公告）日：2008-12-16